The molecular mechanisms of the long noncoding RNA SBF2-AS1 in regulating the proliferation of oesophageal squamous cell carcinoma

Zha, Wenjuan; Li, Xiaomin; Tie, Xiaowei; Yao, Xing; Li, Hao; Gao, Fei; Ye, Ting; Du, Wangqi; Chen, Rui; Liu, Yangchen

doi:10.1038/s41598-020-80817-w

Cited by 8 publications

(4 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SBF2 is associated with cancer by a newly identified long noncoding RNA, SBF2-AS1. SBF2-AS1 was initially characterized in non-small cell lung cancer 34 , and has recently been reported to overexpress in multiple adulthood cancers in East Asian population [35][36][37][38][39][40][41][42][43][44][45][46] . P/LP variants in NOD2 is also a novel discovery in childhood cancers, and intriguingly one variant was found in two siblings who both developed Hodgkin lymphoma.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the genetic basis of familial-associated early-onset hematologic cancers in an ancestral/ethnically diverse population

Feng,

Xu,

Shah

et al. 2024

haematol

View full text Add to dashboard Cite

Genetic predisposition to hematologic malignancies has historically been addressed utilizing patients recruited from clinical trials and pedigrees constructed at major treatment centers. Such efforts leave unexplored the genetic basis of variations in risk by race/ethnic group shown in population-based surveillance data where cancer registration, compulsory by law, delivers universal enrollment. To address this, we performed exome sequencing on DNA isolated from newborn bloodspots derived from sibling pairs with early-onset cancers across California in which at least one of the siblings developed a hematologic cancer, using unbiased recruitment from the full state population. We identified pathogenic/likely pathogenic (P/LP) variants among 1172 selected cancer genes that were private or present at low allele frequencies in reference populations. Within 64 subjects from 32 families, we found 9 LP variants shared between siblings, and an additional 7 such variants in singleton children (not shared with their sibling). In eight of the shared cases, the ancestral origin of the local haplotype that carries P/LP variants matched the dominant global ancestry of study participant families. This was the case for Latino sibling pairs on FLG and CBLB, non-Latino White sibling pairs in TP53 and NOD2, and a shared GATA2 variant for a non-Latino Black sibling pair. A new inherited mutation in HABP2 was identified in a sibling pair, one with diffuse large B-cell lymphoma and the other with neuroblastoma. Overall, the profile of P/LP germline variants across ancestral/ethnic groups suggests that rare alleles contributing to hematologic diseases originate within their race/ethnic origin parental populations, demonstrating the value of this discovery process in diverse, population-based registries.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of the genetic basis of familial-associated early-onset hematologic cancers in an ancestral/ethnically diverse population

Feng,

Xu,

Shah

et al. 2024

haematol

View full text Add to dashboard Cite

show abstract

“…Of interest, by transferring those lncRNAs from chemoresistance GBM tissue or culture to a chemosensitive one, the chemo-sensitive tissue becomes chemoresistant [33] The lncRNA SBF2-AS1 gene is located on chromosome 11p15.1. The proliferation or invasion of many tumor types are associated with altered lncRNA SBF2-AS1 serum levels; Diffuse large B-cell lymphoma, colorectal cancer, hepatocellular carcinoma, serous ovarian carcinoma, clear cell renal cell carcinoma, esophageal squamous cell carcinoma, and lung cancer are associated with increased SBF2-AS1 serum levels [109][110][111][112][113][114][115], while laryngeal squamous cell carcinoma [116] is associated with decreased levels. LncRNA SBF2-AS1 can indirectly alter gene expression by acting as a ceRNA.…”

Section: Long Noncoding Rnas As Serum Biomarkers For Gbm Responsivene...mentioning

confidence: 99%

Serum long non-coding RNAs as potential noninvasive biomarkers for glioblastoma diagnosis, prognosis, and chemoresistance

Eraky¹,

Keleş²,

Goodman³

et al. 2022

J. Integr. Neurosci.

View full text Add to dashboard Cite

Gliomas are common brain tumors with a variable prognosis based on their tumor grade. With glioblastomas, the prognosis is usually unfavorable. Thus, having accurate and rapid methods for their diagnosis and follow-up are essential for rapid discovery of the tumor and to protect patients from unnecessary procedures. Some glioma cases are challenging since there is a limited ability to differentiate between gliomas, recurrent glioblastomas, and single metastatic lesions. Monitoring treatment responses and follow-ups can also be challenging. While both radiological and serological markers have been identified that can aid diagnosis and assess therapies, a particularly promising new class of serological markers are long non-coding RNAs. Long non-coding RNAs are a relatively recently discovered class of regulatory RNA molecules that play critical roles in many cellular and physiological processes. The potential role that long non-coding RNAs play with glioma pathogenic processes is not fully understood. In this literature review, we highlight the potential for long noncoding RNAs to be used as serum biomarkers in glioblastoma patients, including their potential to serve as non-invasive, easy to use, and rapid diagnostic or prognostic indicators.

show abstract

“…Esophageal cancer is a common upper gastrointestinal malignancy that ranks eighth in the world among cancer incidence, especially in China (85)(86)(87)(88)(89). High levels of DRAIC were found in esophageal cancer cells Eca-109, TE-1, EC9706, and OE19 (29).…”

Section: Esophageal Cancermentioning

confidence: 99%

The emerging potentials of lncRNA DRAIC in human cancers

2022

View full text Add to dashboard Cite

Long non-coding RNA (lncRNA) is a subtype of noncoding RNA that has more than 200 nucleotides. Numerous studies have confirmed that lncRNA is relevant during multiple biological processes through the regulation of various genes, thus affecting disease progression. The lncRNA DRAIC, a newly discovered lncRNA, has been found to be abnormally expressed in a variety of diseases, particularly cancer. Indeed, the dysregulation of DRAIC expression is closely related to clinicopathological features. It was also reported that DRAIC is key to biological functions such as cell proliferation, autophagy, migration, and invasion. Furthermore, DRAIC is of great clinical significance in human disease. In this review, we discuss the expression signature, clinical characteristics, biological functions, relevant mechanisms, and potential clinical applications of DRAIC in several human diseases.

show abstract

The molecular mechanisms of the long noncoding RNA SBF2-AS1 in regulating the proliferation of oesophageal squamous cell carcinoma

Cited by 8 publications

References 40 publications

Evaluation of the genetic basis of familial-associated early-onset hematologic cancers in an ancestral/ethnically diverse population

Evaluation of the genetic basis of familial-associated early-onset hematologic cancers in an ancestral/ethnically diverse population

Serum long non-coding RNAs as potential noninvasive biomarkers for glioblastoma diagnosis, prognosis, and chemoresistance

The emerging potentials of lncRNA DRAIC in human cancers

Contact Info

Product

Resources

About